{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:16:13Z","timestamp":1790867773947,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":11627,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1983,11]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Several drugs which react with DNA decrease hepatitis B viral (HBV) DNA polymerase activity in vitro. Because such an alteration of viral replication, if produced in patients with hepatitis B surface antigen (HBsAg)-positive chronic hepatitis, may lead to elimination of viral infection, we conducted a controlled trial of the use of the intercalating agent, quinacrine hydrochloride, in treatment of HBsAg-positive chronic hepatitis. No patient converted from HBsAg positive to negative during the trial and no consistent effect on HBV DNA polymerase activity was noted. Following treatment, elevated transaminase values and alterations of HBV markers were observed in several patients. Fluctuations of transaminase values and HBV markers may reflect alterations in host immunity and viral replication. Quinacrine alone is ineffective in therapy of chronic HBV infection. Additional study with intercalating agents, perhaps in conjunction with other drugs, is suggested.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.1840030609","type":"journal-article","created":{"date-parts":[[2010,7,5]],"date-time":"2010-07-05T12:20:43Z","timestamp":1278332443000},"page":"936-938","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Randomized Controlled Trial of Quinacrine for the Treatment of HBsAg-Positive Chronic Hepatitis"],"prefix":"10.1097","volume":"3","author":[{"given":"Henry C.","family":"Bodenheimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenton","family":"Schaffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Vernace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom Z.","family":"Hirschman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1002\/hep.1840030609-BIB1|cit1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high risk population in the United States","volume":"303","author":"Szmuness","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.1840030609-BIB2|cit2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJM198102123040702","article-title":"Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis","volume":"304","author":"Lam","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.1840030609-BIB3|cit3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.1840020605","article-title":"Prednisolone in HBsAg-positive chronic active hepatitis: histologic evaluation in a controlled prospective study","volume":"2","author":"Wu","year":"1982","journal-title":"Hepatology"},{"key":"10.1002\/hep.1840030609-BIB4|cit4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(80)90442-0","article-title":"Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis","volume":"2","author":"Sagnelli","year":"1980","journal-title":"Lancet"},{"key":"10.1002\/hep.1840030609-BIB5|cit5","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1055\/s-0028-1104782","article-title":"Immunosuppressive therapie der HBs-antigen-positiven und-negativen chronisch-aktiven hepatitis. Erste ergebnisse einer kontrollierten studie","volume":"103","year":"1978","journal-title":"Dtsch Med Wschr"},{"key":"10.1002\/hep.1840030609-BIB6|cit6","first-page":"356","article-title":"Levamisole therapy in chronic active liver diseases","volume":"41","year":"1978","journal-title":"Acta Gastro-Enterologica Belgica"},{"key":"10.1002\/hep.1840030609-BIB7|cit7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM197607222950408","article-title":"Failure of transfer-factor therapy in chronic active type B hepatitis","volume":"295","author":"Tong","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.1840030609-BIB8|cit8","first-page":"10","article-title":"Transfer factor in the attempted treatment of patients with HBsAg-positive chronic liver disease","volume":"30","author":"Jain","year":"1977","journal-title":"Clin Exp Immunol"},{"key":"10.1002\/hep.1840030609-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(73)93321-7","article-title":"Infusion of hepatitis-B antibody in antigen-positive active chronic hepatitis","volume":"2","author":"Reed","year":"1973","journal-title":"Lancet"},{"key":"10.1002\/hep.1840030609-BIB10|cit10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(80)90885-5","article-title":"Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis","volume":"1","author":"Weimar","year":"1980","journal-title":"Lancet"},{"key":"10.1002\/hep.1840030609-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/0016-5085(81)90075-5","article-title":"Adenine arabi-noside therapy in HBsAg-positive chronic liver disease: a controlled study","volume":"80","author":"Bassendine","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.1840030609-BIB12|cit12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(76)92460-0","article-title":"Administration of human fibroblast interferon in chronic hepatitis-B infection","volume":"2","author":"Desmyter","year":"1976","journal-title":"Lancet"},{"key":"10.1002\/hep.1840030609-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1001\/jama.1978.03280430064020","article-title":"Effect of vidarabine on chronic hepatitis B virus infection","volume":"239","author":"Pollard","year":"1978","journal-title":"JAMA"},{"key":"10.1002\/hep.1840030609-BIB14|cit14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/hep.1840010306","article-title":"Antiviral treatment of chronic hepatitis B virus infection: improvement in liver disease with interferon and adenine arabinoside","volume":"1","author":"Scullard","year":"1981","journal-title":"Hepatology"},{"key":"10.1002\/hep.1840030609-BIB15|cit15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/271681a0","article-title":"Inhibition of hepatitis B DNA polymerase by intercalating agents","volume":"271","author":"Hirschman","year":"1978","journal-title":"Nature"},{"key":"10.1002\/hep.1840030609-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(71)91839-3","article-title":"DNA polymerase in preparations containing Australia antigen","volume":"2","author":"Hirschman","year":"1971","journal-title":"Lancet"},{"key":"10.1002\/hep.1840030609-BIB17|cit17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/infdis\/135.6.897","article-title":"Ionic requirements of the DNA polymerase associated with serum hepatitis B antigen","volume":"135","author":"Hirschman","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1002\/hep.1840030609-BIB18|cit18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/gut.23.9.717","article-title":"Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ARA-AMP)","volume":"23","author":"Weller","year":"1982","journal-title":"Gut"},{"key":"10.1002\/hep.1840030609-BIB19|cit19","first-page":"371","volume-title":"Progress in liver diseases","author":"Bianchi","year":"1979"},{"key":"10.1002\/hep.1840030609-BIB20|cit20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0016-5085(81)80002-9","article-title":"Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B","volume":"81","author":"Scullard","year":"1981","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.1840030609","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-198311000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T11:11:32Z","timestamp":1733051492000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-198311000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1983]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.1840030609","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[1983,11]]}}}